OncoMatch/Clinical Trials/NCT04851119

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Is NCT04851119 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Tegavivint for colorectal carcinoma.

Phase 1/2RecruitingChildren's Oncology GroupNCT04851119Data as of May 2026

Treatment: Tegavivint — This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Endometrial Cancer

Melanoma

Neuroblastoma

Ovarian Cancer

Pancreatic Cancer

Sarcoma

Hepatocellular Carcinoma

Tumor Agnostic

Non-Hodgkin Lymphoma

Osteosarcoma

Biomarker criteria

Required: CTNNB1 S37F, S45F, T41A, S45P, S33C, S37C, D32Y, S33F, T41I, G34R, G34V, D32N, S33P, G34E, D32G

the most common CTNNB1 mutations (S37F, S45F, T41A, S45P, S33C, S37C, D32Y, S33F, T41I, G34R, G34V, D32N, S33P, G34E, D32G)

Required: APC loss of function

any loss of function mutations in the APC

Required: AXIN2 loss of function

any loss of function mutations in the ... Axin2FBXW7

Required: FBXW7 loss of function

any loss of function mutations in the ... Axin2FBXW7

Required: TCF7L2 loss of function

any loss of function mutations in the ... TCF7L2

Required: RNF43 loss of function

any loss of function mutations in the ... RNF43

Required: GSK3B gain of function

any gain-of-function mutations in the GSK3B

Required: LRP6 gain of function

any gain-of-function mutations in the ... LRP6

Required: LGR5 gain of function

any gain-of-function mutations in the ... LGR5

Required: CTNNB1 nuclear beta-catenin (strong nuclear staining)

IHC showing strong nuclear beta-catenin staining

Performance status

ECOG/KARNOFSKY/LANSKY 0–2

ECOG scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age

Prior therapy

Cannot have received: tegavivint

Lab requirements

Blood counts

ANC >= 1000/uL; Platelets >= 100,000/uL (transfusion independent); Hemoglobin >= 8.0 g/dL

Kidney function

Creatinine clearance or GFR >= 70 mL/min/1.73 m^2 or age/gender-based creatinine

Liver function

Bilirubin <= 1.5 x ULN for age; ALT (SGPT) <= 135 U/L (ULN=45 U/L); Albumin >= 2 g/dL

See inclusion criteria for detailed thresholds

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Children's Hospital of Alabama · Birmingham, Alabama
Children's Hospital Los Angeles · Los Angeles, California
Children's Hospital of Orange County · Orange, California
Lucile Packard Children's Hospital Stanford University · Palo Alto, California
UCSF Medical Center-Mission Bay · San Francisco, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify